Compare Kimberly Clark Corp (KMB) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Tango Therapeutics Inc. — how do they compare? Kimberly Clark Corp trades at $99.99 (market cap $32.69B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Kimberly Clark Corp is far larger — about 8.7× Tango Therapeutics Inc.'s market cap, and Kimberly Clark Corp pays a 5.21% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kimberly Clark Corp for 94 Days and Tango Therapeutics Inc. for 0 Days on average.
| KMB | TNGX | |
|---|---|---|
Market Cap | $32.69B | $3.75B |
Volume | 6,331,515 | 9,619,106 |
Sector | Consumer Staples | Health |
52-Week High | $121.44 | $32.90 |
52-Week Low | $93.05 | $7.50 |
Typical Hold Time | 94 Days | 0 Days |
Enterprise Value | $38.25B | $2.77B |
Dividend Yield | 5.21% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $99.41, up 0.65% on the day, showing modest recovery after recent declines. The stock faces technical headwinds with bearish moving averages and overbought RSI signals, while fundamentals reveal mixed results with Q2 2026 earnings miss but strong profitability margins. Recent executive transitions and the pending Kenvue acquisition dominate news flow, creating uncertainty around the company's strategic direction and cash flow sustainability.
KMB presents a complex investment case with a 5.16% dividend yield and 54-year dividend growth streak offset by acquisition risks and cash flow concerns. Analyst consensus at $117.25 suggests 18% upside potential, but the stock requires careful monitoring of integration execution and dividend coverage metrics amid changing leadership.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
